Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

Inclusion Criteria: * 1\. Age: 18-65. Unisex. * 2\. Understand trial procedure and content and sign informed consent voluntarily; * 3\. Patients of advanced (phase Ⅲb, multidisciplinary treatment is not appropriate), metastatic (phase IV) or recurrent solid tumor (including melanoma, NSCLC, renal cell carcinoma, head \& neck cancer, esophagus cancer, liver cancer, bladder cancer, spongioblastoma) or lymphoma (classical hodgkin lymphoma and (or) peripheral T-cell lymphoma, natural killer (NK)-T cell lymphoma and mediastinal B cell lymphoma) conformed by histology or cytology and cannot be cured by surgery. There is no effective standard treatment now. * 4\. Agree to provide recorded tumor tissue sample or fresh tissue sample. * 5\. Eastern Cooperative Oncology Group (ECOG): 0-1; * 6\. Expected life ≥ 3 months; * 7\. With at least one measurable and evaluable tumor (solid tumor is subject to criteria for evaluating efficacy of Immune-Related Response Criteria (irRC)/RECIST and lymphoma is subject to criteria/revised criteria of international working group); * 8\. Chemotherapy of the whole body is completed at least 4 weeks before inclusion. * 9\. Radiotherapy of the whole body and partial palliative radiotherapy are completed at least 4 weeks before inclusion. * 10\. Corticosteroids (prednisone\>10mg/d or equivalent) has been stopped at least 2 weeks before inclusion. * 11\. Autotransplantation is completed at least 3 months before inclusion. * 12\. Major surgeries with the ne…